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Abstract 
Successful aging depends in part on delaying age-related disease (ARD) onsets until 
later in life. Conditions including coronary artery disease, Alzheimer’s disease, prostate 
cancer and type 2 diabetes are moderately heritable. Genome Wide Association Studies 
(GWAS) have identified many risk associated single nucleotide polymorphisms (SNPs) 
for these conditions, but much heritability remains unaccounted for. Nevertheless a great 
deal is being learned: here we review ARD associated SNPs and identify key underlying 
pathways including lipid handling, specific immune processes, early tissue development 
and cell cycle control. Most ARD associated SNPs do not affect coding regions of genes 
or protein makeup, but instead influence regulation of gene expression. Recent evidence 
indicates that evolution of gene regulatory sites is fundamental to interspecies 
differences. Animal models relevant to human aging may therefore need to focus more 
on gene regulation rather than testing major disruptions to fundamental pathway genes. 
 
Recent larger scale human studies of in-vivo genome wide expression (notably from the 
InCHIANTI aging study) have identified changes in splicing, the ‘fine tuning’ of protein 
sequences, as a potentially important factor in decline of cellular function with age. 
Studies of expression with muscle strength and cognition have shown striking 
concordance with certain mice models of muscle repair and beta-amyloid phagocytosis 
respectively.  
 
The emerging clearer picture of the genetic architecture of ARDs in humans is providing 
new insights into the underlying pathophysiological pathways involved. Translation of 
genomics into new approaches to prevention, tests and treatments to extend successful 
aging is therefore likely in the coming decades.  
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 1 Introduction 
 
While there is much debate about the processes driving human aging, there is little 
doubt that genetic influences play a significant role 1. Humans clearly live very much 
longer than the currently favored laboratory models of aging, and such interspecies 
differences in reproductively ‘fit’ lifespan must have an inherited genetic foundation. 
Within human populations, environmental and behavioral exposures are important but at 
least a quarter of life expectancy variation in twin or family studies is attributable to 
inherited genetic or epigenetic factors 2. Age related conditions such as type 2 diabetes, 
myocardial infarction, common cancers and Alzheimer’s disease typically have onsets 
after the fourth decade of life; ‘successful’ agers delay these onsets until relatively late in 
life 3. Many aging traits and diseases show moderate heritability, including 
cardiovascular disease 4 and impaired physical functioning 5, independent of known 
environmental risk factors.  
 
Inherited genetic variations in DNA sequences come in several forms, including single-
nucleotide polymorphisms (SNPs), insertions/deletions and copy-number variations. Of 
the 54 million variants documented in dbSNP 6 >88% are single base-pair substitutions 
or ‘SNPs’ 7. SNPs located close to one-another are more likely to be inherited together 
(called linkage disequilibrium) 8 and this tendency coupled with new array technology 
allows the assaying of millions of SNPs per sample, capturing most common variation.  
 
The effect a variant has on a given phenotype depends on its position in the genome. 
Within each gene only a small proportion of the DNA sequence is used as a template for 
assembling amino-acids into specific proteins 9 (Fig.1); these DNA sections are termed 
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exons. Exon sequences are ‘transcribed’ (in part or in full) from DNA into messenger 
RNA (mRNA), which undergoes ‘processing’ before forming the template for protein 
production. If the DNA sequence within an exon is changed, this could have profound 
consequences to the final structure of the protein synthesized from the gene. However, 
the protein-coding regions of genes are highly conserved, even between species 10. This 
highlights an intriguing question; if highly similar genes are used in the growth and 
development of different organs, tissues and cell-types in individuals, how can so much 
phenotypic variation occur? The answer lies in the complex machinery that regulate 
gene transcription and protein production in different cells types and in response to 
specific stimuli.  
 
Transcription can vary in amount (i.e. particular mRNAs can be up or down regulated) 
but can also produce specific versions or ‘isoforms’ of proteins, in a fine tuning system 
that contributes to specialization of cell types and tissues. This involves the removal, or 
‘splicing’, of introns - sequences of DNA that separate the exons from one-another - 
allowing many protein products to be derived from a single gene. Transcription and RNA 
processing require extensive regulation by transcription factors binding to sites in 
proximity to the gene, which can be many thousands of base pairs away. DNA variants 
located within these regulatory binding sites can alter when, where and for how long a 
gene is expressed by altering the affinity of the various transcription factors to that 
particular regulatory sequence (Fig.1). 
 
Differential regulation of genes – both in location and timing – between species likely 
contributes to the divergence and isolation of different species 11. Human studies are 
lacking, but work in mice has shown regulatory differences between sub-species 12. 
Affordable genomic array technologies that measure the expression of thousands of 
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genes are now being used in human population studies. Progress in this field is likely to 
receive a boost in the coming years as studies use large sample collections to 
investigate the differential regulation of gene expression in humans, and how these 
differences influence disease and longevity 13. 
 
Epigenetic changes, such as DNA methylation and histone modifications, are also 
heritable and affect mRNA expression 14. These changes to the structure of DNA do not 
affect the sequence, and can change with advancing age 15. It appears that genetic and 
epigenetic variations exert their effects by altering either the amount of RNA transcribed 
from a gene, or the relative proportion of alternatively expressed isoforms produced by 
the alternative splicing mechanisms. These ultimately affect other downstream elements 
of the pathway, such as binding partners or inhibitors, resulting in a change in 
phenotype. It will therefore be necessary for future research programs to integrate 
genetic variation, epigenetics and associated gene expression profiles to understand the 
origins of heritable traits and diseases. Such mechanistic understanding may contribute 
to the discovery of new therapeutic targets for aging pathologies 16. 
 
 
2 SNPs and age related diseases 
 
In the early 2000s, many correlations between SNPs and specific disease were reported 
from relatively small-scale volunteer and population studies, but unfortunately multiple 
statistical testing and a bias towards reporting positive results contributed to many of 
these reports being unreliable, with inflated effect sizes and replication efforts failing to 
confirm claims 17,18.By 2006 Genome-wide association studies (GWAS) had became 
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popular, using large numbers of subjects to identify the SNPs most strongly associated 
with a wide range of diseases and phenotypes. Stringent rules for statistical significance 
and large collaborations aimed at pooling data into enormous meta-analyses have 
produced many robust findings: in aging the CHARGE consortium have led the way 
(http://web.chargeconsortium.com/) 19.  
 
Many striking findings have emerged from GWAS studies to deepen our understanding 
of successful aging. One of the first breakthroughs was in a GWAS study of age-related 
macular degeneration (AMD), which identified a SNP related to complement factor H 20, 
this has since been replicated in larger studies 21,22. As complement factor H (part of a 
specialized inflammatory cascade) had previously attracted limited attention in AMD 
research, GWAS had provided a powerful insight into the underlying mechanisms of the 
condition; at present 40% of the heritability of AMD has been accounted for by 5 SNPs 
23. Similar insights into the mechanisms underlying menopause, a key aging trait in 
humans, have very recently emerged from a meta-analysis of numerous studies 24. 
Variants related to DNA repair and immune pathways emerged as important.  
 
Using the catalogue of published GWAS results 25 we have re-examined the results for 4 
common age-related diseases (ARDs) for this review, to illustrate the lessons being 
learned from GWAS about the biological architecture of these conditions. We have 
extracted the SNP results for Alzheimer’s disease (AD), cardio-vascular disease (CVD), 
prostate cancer (PC) and type 2 diabetes mellitus (T2D). We included only robustly 
associated variants; studies with more than 500 cases/controls were selected, and SNPs 
with genome wide statistical significance (associations at p<1*10-8). At the time of writing 
(January 2012) 75 SNPs associated with CVD met these criteria, 67 for T2D, 55 for PC 
and 28 for AZ (Table 1). As some of these SNPs are in linkage with one-another we 
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have only considered the nearest genes in our analysis: for instance gene TCF7L2 was 
only included once, even though several T2D SNPs map to it. 
 
Of the SNPs associated with these 4 ARDs only one is not unique to a single disease 
(rs2075650 increases risk of both Alzheimer’s and cardiovascular disease). A critical 
feature of the identified SNPs is that very few are in protein-coding regions (4% of these 
ARD related SNPs are classified as exonic), therefore most do not directly alter the 
amino acid sequence of the protein product (Fig.2). We therefore identified the nearest 
genes to each SNP, as the most likely genes affected, although in most cases the 
mechanisms of effect have yet to be confirmed. Only 5 of the 89 ARD SNP nearest 
genes are associated with more than one ARD; MTHFD1L (AD and CVD), OASL (CVD 
and T2D), SLC22A3 (CVD and PC), THADA (PC and T2D) and TOMM40 (a proxy for 
the ApoE haplotype, for AD and CVD). In general therefore, our exemplar ARD appear 
to be complex polygenic traits (i.e. influenced by many genes of small effect) and these 
risk traits appear to be largely inherited separately in each individual. We note however 
that much variation remains unaccounted for, but it is likely that this unexplained 
heritability will be accounted for by large numbers of very small effect common variants, 
rare moderate effect variants 26 or perhaps epigenetic effects. Another contributor to the 
missing heritability might be that heritability estimates are uncertain: twin studies have 
estimated the genetic heritability of AD anywhere between 36% 27 and 74% 28, partly 
depending on definitions used.  
 
 
 
2.1 Biological pathways implicated in ARD SNPs 
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As noted for macular degeneration, the results from SNP studies can give a powerful 
indication of the biological pathways contributing to each trait. Using this principle we 
have analyzed the GWAS results for 4 common ARDs to identify the affected biological 
pathways. Using the published GWAS results 25 we extracted the SNPs listed for the 4 
common ARDs mentioned above. SNP annotations (mapped genes) were determined 
using SCAN 29. We used BiNGO 30 software to determine which biological processes (as 
defined by Gene Ontology 31) were statistically overrepresented in the sets of genes 
derived from the GWAS SNPs for each of the ARDs. The biological processes involved 
in the ARDs are listed in Table 1 (lists have been summarized to eliminate redundancy - 
full gene lists and BiNGO results can be found in supplementary tables 1 and 2 
respectively).  
 
The findings for type 2 diabetes (T2D) illustrate how this approach can identify the 
mechanisms underlying a disease. T2D-related pathways included regulation of insulin 
secretion and glucose homeostasis, clearly confirming the known etiology: if the causes 
of T2D were unknown the SNPs would have pointed us in the right direction. However, in 
addition to the known pathways, cell cycle arrest and RNA modification were also 
prominent. The cell cycle control genes associated with T2D seem to be involved in 
maintaining or compromising beta cell mass in the pancreas, while recent expression 
studies have shown RNA processing changes to be strongly age-associated in humans 
32. 
 
Biological processes highlighted by the genes with mapped variants associated with 
CVD are mostly related to lipid digestion, transport, localization and clearance, although 
the largest single effect variant (at 9p21) is thought to influence repair and regrowth of 
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the intima of arteries, and is associated with peripheral arterial disease 33 in older 
populations and excess mortality until late in life 34. 
 
SNPs affecting the risk of developing prostate cancer are largely in development and 
proliferation related processes. Although some of the processes seem specific to certain 
organs, the underlying development mechanisms involve similar pro-growth and 
development genes. Given that cancer is a disease of faulty control over cell proliferation 
or apoptosis, components of these pathways, or similar, would be expected to be 
overrepresented in the genes associated with susceptibility to prostate cancer. 
 
Given that the causes of Alzheimer’s disease (AD) are still largely mysterious, the 
GWAS results for AD are of particular interest. Pathways implicated in AD based on the 
mapped SNPs were mostly related to lipid and cholesterol processing, and specific 
inflammatory pathways. This may reflect the role of neuro-inflammation, implicated as 
possibly related to beta-amyloid deposition, a core feature of AD 35. The best studied loci 
for AD is the ApoE Epsilon 4 (E4) haplotype, identified as disrupting the normal 
functioning of ApoE in the distribution of lipids in the central nervous system 36.  
 
2.2 The genetic architecture of age-related conditions  
Although a few ARD associated SNPs may involve amino acid changing variants (e.g. the 
R325W variant in SLC30A8 gene, the P12A variant of the PPARG gene and the E23K 
variant of the KCNJ11 gene for type 2 diabetes) 37,38, it is striking that over 98% of all 
variants are located in ‘non-coding regions’ of the genome 6,7 (Fig.2), only 60% are 
predicted to alter the final protein sequence (similar proportions in GWAS results: <5% of 
reported SNPs change the final protein sequence, ~46% intergenic, ~41% intronic, the 
rest are in other untranslated regions (UTRs)). Although these non-translated regions of 
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the genome produce no proteins, there is growing evidence that they are far from non-
functional 39.  
 
Genetic variants in non-translated regions may affect factors necessary for epigenetic 
modifications, such as histone modification, chromatin remodeling, miRNA (microRNA) 
regulation of transcription or DNA methylation. These factors are recognized as 
important regulators of the activity of many genes, including those involved in glucose 
metabolism 40,41. Variants located within a regulatory region of a transcript (for instance 
the UTRs)  may interfere with the efficiency of transcription or translation (Fig.1), as has 
been recently shown for several human and rodent genes 42–44. Variants located in 
introns may be present in uncharacterized exons, or may influence mRNA splicing 45; the 
production of aberrant splice products is an important disease mechanism 46,47. Finally, 
SNPs located in intergenic regions may act through natural antisense transcripts (NATs) 
48 or be located in uncharacterized regulatory regions as was described in 2008 for the 
OCA2 gene involved in determination of eye color in humans 49.  
 
Most of the non-coding regulatory regions are involved in the generation of tissue 
specificity, adaptation or response to the intra- and extracellular environment. Alternative 
splicing, for example, is a pivotal mechanism in ensuring cellular plasticity. It is 
noteworthy that organisms such as the dinoflagellates that do not exhibit phenomena 
such as alternative splicing have a great many more genes (up to 87,688) 50 than do 
higher organisms such as humans (~23,000 genes). In order to make any further 
inference about how variation at the DNA level leads to changes in gross phenotype we 
must now look downstream at changes in gene expression associated with genetic 
variation, aging and age-related disease. 
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2.3 Comparison with laboratory models of aging 
Laboratory models typically used to study aging, such as C. elegans (nematode worm) 
and Mus musculus (mice), have drastically shorter lifespans than our own (~3 weeks 51 
and ~3 years 52 respectively, versus a 122 year maximum for humans thus far 53). In 
some respects these models are ideal for study in the laboratory (higher turnover, 
controlled environment), yet applicability to humans can be elusive due to the inherent 
inter-species differences. For instance, whilst we may share a large portion (over 98.5% 
identical in protein-coding regions54) of our genome with chimpanzees - our closest 
relative in evolutionary terms - we have evolved distinct phenotypic differences, including 
aging at a slower rate. These differences will only be more exaggerated in more distantly 
related species (such as the worm and mouse models). There are however similarities 
between aged humans and aged model organisms; they all tend to have decreasing 
overall fitness, and therefore studies using model organisms continue as they may be at 
least indicative of some aging mechanisms in humans. 
 
Extensions to lifespan in model organisms are mostly associated with disruption to 
fundamental metabolic pathways, with target genes showing conservation across 
species. For example, ‘knockout’ mutations in the IGF1/insulin pathway can double 
lifespan in C.elegans in the laboratory environment 55, and some have argued that this is 
directly relevant to humans. However, aging traits in higher organisms are likely to be 
largely influenced by complex and cell type specific regulatory sites, as noted above. 
Given the barriers against experimental studies of in-vivo regulation and aging in 
humans, epidemiological studies combining genetic and gene expression data will be 
crucial in determining the relevance to humans of molecular mechanisms identified in 
laboratory models. 
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3 Gene expression arrays 
 
Messenger RNA (mRNA) is a key intermediate between DNA and proteins (Fig.1). Cells 
tightly regulate the amount and form of new proteins produced in response to intra- and 
extra-cellular signals. The amount of mRNA being produced at any point in time is a 
good proxy for the demand within the cell for the corresponding protein. This allows us a 
unique insight into how, at a cellular level, organisms react to stimuli. By profiling this 
expression of mRNA we can infer the molecular mechanisms associated with 
phenotypes such as disease, or genotype. For example Song et al. 56 have shown that 
~17% of genes are differentially expressed between 2 populations of distinct ethnic 
decent, which is due to differences in inherited variation and lifestyle (environment) 57.  
 
Microarrays are used to quantify the expression of thousands of mRNA molecules from a 
single sample. Many gene expression studies in laboratory models of aging have been 
reported: see the database of age-related genes 58. Until recently however studies in 
humans were based on very small sample sizes, risking the same reliability problems 
that beset candidate SNP studies. As microarray cost has come down drastically in 
recent years it is now feasible to study large numbers of samples at once.  
 
In humans major early studies focused on, for example, gene expression in muscle 
biopsy material 59 and identifying genes associated with age in the San Antonio Family 
Heart Study frozen lymphocyte samples60. Comparing results across studies and with 
the in-vivo situation has been difficult as sample collection, cell separation and storage 
Journal of Gerontology Series A: Biological Sciences and Medical Sciences, 2012 
 
 
13 
processes can alter mRNA concentrations in unpredictable ways. Recent work by the 
author group and collaborators in the InCHIANTI study of aging 61 have used recent 
technology to collect in-vivo mRNA levels to explore aging and age-related phenotypes 
in a cohort of 698 individuals that are representative of the general population. 
Microarrays were used to quantify the expression of 16,571 mRNA transcripts in each 
individual, from circulating leukocytes in blood. As blood is relatively easily collected in 
large population samples and is likely to be the main tissue for clinical application of 
gene expression signatures, blood derived leukocytes are the first choice for in-vivo 
studies, with research programs to follow up findings in other tissues or in-vitro.  
 
After adjustment for potentially confounding factors, only 2% (295) of the 16,571 probes 
tested in InCHIANTI were robustly associated with age 32, and the majority of these were 
down-regulated. Using gene ontology information in a pathways-based analysis we 
found that the most deregulated biological processes across the age range are related to 
RNA processing 31,62. mRNA splicing is the process that allows a single gene to code for 
more than one transcript (‘isoform’), which may have a different function, temporal or 
spatial expression pattern to an alternative isoform from the same gene. The implications 
of this finding are wide-ranging; a decrease in the production of mRNA splicing factors is 
indicative of a general loss of specificity or ‘fine tuning’– the alternative forms of genes 
will be less common in the older individuals. This may mediate some of the decreased 
‘fitness’ and declining ability of cells to respond to stresses with advancing age. 
 
Using only 6 of the mRNA probes studied, it was possible to very efficiently distinguish 
between old and young individuals in a independent confirmatory subset of study 
respondents (for methods and detailed results see the paper 32), suggesting that gene 
expression biomarkers of human biological aging may soon be validated.    
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3.1 Gene expression and age-related traits 
 
Age-related pathologies themselves can also reveal mechanisms intrinsic to the aging 
process. Loss of muscle strength is a characteristic feature of aging, and can lead to 
sarcopenia and frailty. We found that the strongest gene expression association with 
muscle strength in our human subjects pinpointed a highly plausible mechanism. After 
adjustment for confounding factors, a transcript of CCAAT/enhancer-binding protein-beta  
(CEBPB) showed the strongest association with human strength, across a wide age 
range 63. CEBPB is a gene involved in the maintenance and repair of damaged muscle 
fibers by macrophages. A mouse model of disrupted CEBPB signaling produced 
myocyte loss and fibrosis, reminiscent of sarcopenia 64. Finding, for the first time, that 
CEBPB expression is so closely associated with human muscle strength suggests that 
the macrophage mediated repair pathways should be a priority for investigations of age 
related declines in muscle, particularly in light of recent findings that strength is 
predictive of mobility decline in older adults 65. 
 
We have also examined expression associations with cognitive function, using the mini 
mental state examination (MMSE) score 66. It has been argued that chronic inflammation 
contributes to impaired cognitive function and dementia 67,68, so we expected to find 
many related expression correlates. In fact, we found that the strongest association was 
with a single chemokine receptor (CCR2), with little other robust evidence of gene 
expression deregulation (Fig.3). CCR2 is involved in the macrophage response to 
atherosclerotic plaque formation and in brain microglia. Blocking CCR2 signaling in mice 
models of Alzheimer’s disease resulted in accelerated Alzheimer’s-like pathologies 69 
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and transplantation of ‘normal’ hematotpoietic CCR2 competent monocytes restored 
memory capacities 70. This is another strong indication of concordance between human 
in-vivo leukocyte gene expression and one of the many laboratory models of Alzheimer’s 
disease. 
 
While gene expression studies in humans therefore appear promising, there remain 
major challenges. As noted above, gene expression can be affected by confounders 
such as lifestyle and ethnicity57. RNA is an unstable molecule and specimen handling is 
a challenge. Perhaps the greatest challenge in studying human aging is the limited 
access possible to many tissues of interest. Nevertheless, expression arrays using RNA 
from available tissues such as blood are helping to identify novel age related expression 
signatures and have pinpointed concordance with specific laboratory models of key 
traits.  
 
 
4 Could genomics be part of ARD risk or diagnostic testing? 
 
In the excitement of the human genome sequencing project, many argued that genomics 
would predict common diseases and personalize treatment. However, this optimism 
waned as it became clear that most common diseases are influenced by very large 
numbers of variants of small effect (plus strong environmental influences), and that much 
variation is still unaccounted for 71. 
One of the first SNPs to be identified for type 2 diabetes was the TCF7L2 variant, which 
was associated with a significant increase in risk (OR = 1.56, 95% CIs = 1.41 to 1.73, p 
= 4.7x10
-18
) 
72
. Could this marker be useful for disease prediction? Rates of type 2 
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diabetes increase with age, and studying older populations provides the best indication 
of how effective the prediction might be. In fact, we found that most (>80%) of those 
carrying the ‘risk’ TCF7L2 alleles in the InCHIANTI population study of aging had not 
developed diabetes, and many of those with diabetes did not have the risk variant 73. If 
the larger effect variants are not predictive, could panels of variants be useful? 
Potentially they could: a set of lipid altering variants do predict whether older people are 
over treatment thresholds for HDL and LDL cholesterol 74, although the prediction is 
never likely to be precise. Adding gene variant panels into screening program algorithms 
may also be of some utility, for example in breast cancer screening 75. 
 
The key to a useful test is, of course, having an effective intervention to offer if the test is 
‘positive’. The success in identifying a good proportion of the heritability in age-related 
macular degeneration is likely to be translated into a useful predictive test when a 
preventive treatment becomes available. Each clinical application however needs to be 
properly investigated using a systematic approach to test evaluation, as initial data in 
preselected case and control groups tends to seriously exaggerate test efficiency 76.   
 
In addition to risk prediction, there is some optimism about the potential for ARD variants 
to identify new drug targets: for example, six type 2 diabetes variants are in or near 
targets for existing drugs, and there is therefore optimism that novel SNP loci might lead 
to new drug targets 77.  
 
In contrast to SNP based tests, gene expression markers are already being used to 
guide disease sub-typing and treatment selection, notably in breast 78 and other cancers. 
The tests involved use mainly tumor tissue itself as the source of mRNA, but extension 
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of this approach to identifying gene expression ‘signatures’ early in disease processes 
seems likely. In the case of age related changes we have shown that a panel of 6 
markers related to immunity and inflammation, maintenance/development of muscle 
tissue and vascularization are highly predictive of age in a confirmatory subset 32, but 
such expression gene signatures of aging will need extensive and independent 
validation.  
 
 
5 Conclusions 
 
Aging is a heterogeneous process that includes rapidly rising risks of age-related 
diseases (ARDs). Delaying onset of common ARDs (including cardiovascular disease, 
Alzheimer’s disease, prostate cancer and type 2 diabetes) is a major element in 
‘successful’ aging. GWA studies have identified many risk genetic variants for ARDs, but 
a lot of variability remains to be identified. Despite this, risk SNPs are shedding new light 
on the underlying biological pathways involved in ARDs, with notable new insights in age 
related macular degeneration, Alzheimer’s disease and several age related cancers.  
 
GWAS studies have helped to change our ideas about the genetic architecture of ARDs. 
The majority of ARD risk variants are not in coding regions and few influence the 
structure of proteins themselves. Instead most variants appear to affect gene expression 
and the processing of RNA, often in cell or tissue type specific ways. Emerging evidence 
supports evolution of regulatory sites as a key driver of interspecies differences. Such 
evolution of gene regulation allows complex specialization of biological functions while 
conserving the basic structure of fundamental genes across species. More caution may 
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therefore be needed in extrapolating from laboratory models of aging involving disruption 
of apparently conserved metabolic pathway genes. We suggest therefore that animal 
models of aging may need to focus more on regulatory processes, and that human 
studies of gene regulation and expression are needed to test the relevance of each lab 
model finding to humans.  
 
In larger scale gene expression studies, we have shown that RNA processing and 
alternative splicing, the ‘fine tuning’ of protein sequences, may be a potentially important 
factor in loss of cellular function with advancing age in humans. Analyses of expression 
changes in age-related traits including muscle strength and cognitive function have also 
pinpointed concordance with specific animal model findings. Such genome wide studies 
are likely to help focus research in humans on the most relevant mechanisms from 
laboratory models, although access to a wider range of relevant tissues is a major 
barrier.   
 
The time taken for new scientific technologies to produce new tests and treatments is 
often initially underestimated, and this certainly applies to the genomics of ARDs. 
Nevertheless, the synergy of  ‘-omics’ technologies across genetic, epigenetic and 
transcript variations is already leading to better understanding of the fundamental 
processes underlying human aging and related disease. New modes of prevention and 
treatment of age-related diseases are likely to follow in the coming decades, although 
much remains uncertain.  
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Figures 
 
 
 
Figure.1 The central dogma – extensive regulation provides specificity 
Gene expression in higher organisms requires regulation that is often specific to cell-type 
and is responsive to the cells environment. Here we show an example of a gene being 
transcribed, the RNA being processed and spliced, and then finally translated into a 
sequence of amino-acids: a protein. Changes to the DNA sequence within the regulatory 
sites could result in transcription factors failing to bind, or an intron to be incorrectly 
processed, etc, all of which will affect the downstream biological pathway.  
Abbreviations: UTR = untranslated region, Poly-A tail = RNA ‘tail’ sequence consisting of 
many adenosine nucleotides. 
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Figure.2 Classification of variants in dbSNP 
Types of DNA sequence variation (from dbSNP, build 1356, summary estimates by Dan 
Koboldt 7. Only 2% of all variants are in protein coding regions, the rest are either 
unknown (intergenic - not located near a protein-coding gene), intronic (within genes, but 
non-coding) or ‘other’, which include those in the UTR (un-translated region) and ‘near 
gene’. The protein-coding variants have been further classified by final protein function; 
they can be missense (causes an amino-acid substitution), nonsense (causes premature 
termination), silent (no change to amino-acid sequence) or frameshift (changes the 
translation ‘frame’) mutations. 
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Figure.3 The relationship between CCR2 gene expression and MMSE score 
This plot shows the fitted association (adjusted for confounding factors) between 
standard deviation differences in CCR2 gene expression levels by MMSE scores in the 
InCHIANTI population, from a penalized cubic spline regression model. 
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Table 1. Biological pathways in age-related disease: biological processes statistically 
overrepresented in the GWAS results for 4 common age-related diseases (ARDs): 
Alzheimer’s disease (AD), cardio-vascular disease (CVD), prostate cancer (PC) and type 
2 diabetes mellitus (T2D). 
 
Age-related disease Studies SNPs Genes* Biological Pathways P-value 
Alzheimer's disease 14 28 11 Lipid transport 7.30E-03 
    Regulation of receptor-mediated endocytosis 7.30E-03 
    Positive regulation of immune response 7.30E-03 
    B cell mediated immunity 9.90E-03 
    Positive regulation of response to stimulus 9.90E-03 
      
Cardio-vascular disease 10 75 42 Lipoprotein catabolic process 2.30E-02 
    Sterol transport 2.30E-02 
    Low-density lipoprotein particle clearance 2.30E-02 
    Lipid digestion 2.70E-02 
    Intestinal absorption 4.60E-02 
      
Prostate cancer 12 55 16 Pancreas development 4.60E-03 
    Epithelial cell proliferation 2.80E-02 
    Regulation of embryonic development 2.80E-02 
    Endocrine system development 4.10E-02 
    Kidney development 4.60E-02 
      
Type 2 diabetes 22 67 25 Regulation of insulin secretion 2.40E-04 
    Cell cycle arrest 1.90E-02 
    Stem cell development 2.00E-02 
    RNA modification 3.20E-02 
    Glucose homeostasis 3.20E-02 
      
Notes: ARD = Age-related disease. * Number of mapped genes (not all SNPs map to genes – multiple SNPs can map to a 
single gene). P-values represent the strength of the association between the list of derived genes (from the SNPs list) and 
the biological process. 
Source: gemone-catagloue (www.genome.gov/gwastudies) 
